A new market study has found that people using GLP-1 receptor agonist medications spend significantly more on fragrances than the average consumer — the latest evidence the medications reshape how users experience sensory reward.
Market researcher NIQ, studying US consumers, found that GLP-1 users spent 26% more on fragrances than the typical person. The findings circulated this week as major fragrance houses begin studying how the medications affect consumer preferences.
What Happened
The NIQ data points to a measurable behavioral shift: as GLP-1 medications suppress appetite and dampen food's reward response, users redirect spending toward other sensory enjoyment — and fragrance, particularly sweet, dessert-like gourmand scents, is a leading beneficiary.
Reporting that drew on interviews with eight fragrance manufacturers and perfume brands found that ingredient house IFF has conducted internal research suggesting GLP-1 therapies may spark greater interest in scent as a source of sensory pleasure. L'Oreal has drawn similar conclusions, with a global brand president noting that users compensate for the pleasure of food and taste with other forms of enjoyment.
Swiss fragrance house Givaudan, which has been studying the link for roughly a year, found that GLP-1 use can shift fragrance preferences in unpredictable directions — some once-loved scents become repellent while new ones become appealing — with the overall effect being increased interest in fragrance.
Who Is Affected
- GLP-1 medication users, who may notice changes in smell, taste, and food-linked cravings while using the drugs
- Fragrance and beauty brands, already repositioning product lines around gourmand and dessert-inspired scent profiles
- Chemosensory researchers, including scientists at the US National Institutes of Health, where the National Smell and Taste Center is examining how GLP-1 drugs affect olfactory processing
Timeline
- Early 2020s — GLP-1 receptor agonists rise as weight-management therapies
- 2024–2025 — Gourmand fragrances (vanilla, caramel, dessert-inspired scents) become a dominant perfume market trend
- 2025 — Givaudan begins studying the connection between GLP-1 use and fragrance preference
- October 2026 — NIQ's US consumer data quantifies the shift at 26% higher fragrance spending
What This Means for Researchers
The consumer data sits on top of a credible biological question. GLP-1 receptors are expressed in brain regions involved in appetite and reward, and researchers have documented taste and smell changes during therapy. A chemosensory effect is not far-fetched, as National Smell and Taste Center leadership has noted — though it is too early to predict durable shifts in odor perception.
For the research community, the fragrance data matters less as a cosmetics story and more as evidence that GLP-1s modulate the broader reward system, not just appetite. Reports of reduced alcohol cravings, reduced impulse shopping, and altered smell and taste all point the same direction: the medications appear to change the value the brain assigns to multiple rewarding stimuli.
How to Verify Your Peptides
Any documented outcome depends on an authentic, correctly manufactured product. If you research GLP-1 compounds, independent verification is the baseline:
- Start with how peptide testing works to understand purity, identity, and fill-weight checks
- Compare methods in our HPLC vs LC-MS breakdown
- Review identity, purity, and fill-weight verification before relying on any COA
- See our trusted third-party testing guidance
Safe Alternatives
Concerned about product quality in an unregulated gray market? Our peptide research library covers compounds with published characterization data, and our vendor directory lists suppliers with documented testing practices.
Sources
- Industry reports on GLP-1 consumer spending and fragrance trends (October 2026)
- Peer-reviewed chemosensory research on GLP-1 receptor agonists
- Public statements by fragrance industry research and development leadership